US Has Opportunity To Lead On Ophthalmic Biosimilars
Cardinal Health’s Sonia Oskouei Expands On Findings Of 2022 Biosimilars Report
• By David Wallace
Cardinal Health says 2022 will be a turning point for US biosimilars • Source: YAY Media AS / Alamy Stock Photo 
